Celgene Switzerland Llc - Net Worth and Insider Trading

Celgene Switzerland Llc Net Worth

The estimated net worth of Celgene Switzerland Llc is at least $6 Million dollars as of 2024-04-27. Celgene Switzerland Llc is the 10% Owner of Jounce Therapeutics Inc and owns about 3,456,463 shares of Jounce Therapeutics Inc (JNCE) stock worth over $6 Million. Details can be seen in Celgene Switzerland Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Celgene Switzerland Llc has not made any transactions after 2017-02-01 and currently still holds the listed stock(s).

Transaction Summary of Celgene Switzerland Llc

To

Celgene Switzerland Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Celgene Switzerland Llc owns 3 companies in total, including Agios Pharmaceuticals Inc (AGIO) , Juno Therapeutics Inc (JUNO) , and Jounce Therapeutics Inc (JNCE) .

Click here to see the complete history of Celgene Switzerland Llc’s form 4 insider trades.

Insider Ownership Summary of Celgene Switzerland Llc

Ticker Comapny Transaction Date Type of Owner
AGIO Agios Pharmaceuticals Inc 2019-11-12 10 percent owner
JUNO Juno Therapeutics Inc 2018-03-05 10 percent owner
JNCE Jounce Therapeutics Inc 2017-02-01 10 percent owner

Celgene Switzerland Llc Latest Holdings Summary

Celgene Switzerland Llc currently owns a total of 1 stock. Celgene Switzerland Llc owns 3,456,463 shares of Jounce Therapeutics Inc (JNCE) as of February 1, 2017, with a value of $6 Million.

Latest Holdings of Celgene Switzerland Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
JNCE Jounce Therapeutics Inc 2017-02-01 3,456,463 1.88 6,498,150

Holding Weightings of Celgene Switzerland Llc


Celgene Switzerland Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Celgene Switzerland Llc has made a total of 0 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years. The most-recent trade in Jounce Therapeutics Inc is the acquisition of 625,000 shares on February 1, 2017, which cost Celgene Switzerland Llc around $10 Million.

Insider Trading History of Celgene Switzerland Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Celgene Switzerland Llc Trading Performance

GuruFocus tracks the stock performance after each of Celgene Switzerland Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Celgene Switzerland Llc is 66.53%. GuruFocus also compares Celgene Switzerland Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Celgene Switzerland Llc within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Celgene Switzerland Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Celgene Switzerland Llc

Average Return

40.32%

Average return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 24.34 66.53 -25.16 40.32 -49.26 -28.36
Relative Return to S&P 500(%) 19.23 61.76 -33.79 16.52 -58.22 -40.64

Celgene Switzerland Llc Ownership Network

Ownership Network List of Celgene Switzerland Llc

No Data

Ownership Network Relation of Celgene Switzerland Llc


Celgene Switzerland Llc Owned Company Details

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Celgene Switzerland Llc is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Legal Officer James William Burns , Chief Medical Officer Sarah Gheuens , and Principal Accounting Officer Washburn Theodore James Jr. .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Celgene Switzerland Llc made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 205,692 shares made by David P Schenkein , a net sale of 8,791 shares made by Washburn Theodore James Jr. , and a net sale of 14,160 shares made by James William Burns .

In summary, during the past 3 months, insiders sold 93,495 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 93,495 shares. During the past 18 months, 358,881 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 358,881 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

Celgene Switzerland Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Celgene Switzerland Llc. You might contact Celgene Switzerland Llc via mailing address: Aon House, 30 Woodbourne Avenue, Pembroke D0 Hm 08.

Discussions on Celgene Switzerland Llc

No discussions yet.